TCR1188-ABC Cells in KRAS-mutated Cancers
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma, cholangiocarcinoma, colorectal cancer, or non-small cell lung cancer (NSCLC) will be targeted for participation. Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony nowotwór zaawansowany: rak trzustki, dróg żółciowych, jelita grubego lub płuc
- •Posiadanie specjalnego markera genetycznego HLA-A*11:01 (potwierdzony w laboratorium)
- •Posiadanie mutacji KRAS G12V potwierdzonej w badaniu genetycznym
- •Wcześniejsze leczenie raka (przynajmniej jedno leczenie standardowe)
- •Widoczne ogniska nowotworu potwierdzone w obrazowaniu (ostatnie 8 tygodni)
- •Prawidłowe funkcjonowanie nerek i wątroby (zbadane w ostatnich 4 tygodniach)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Pennsylvania
Philadelphia, United States
Trial contact
Abramson Cancer Center Clinical Trials Service
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.